EP4329729A4 - Composition pharmaceutique de pembrolizumab et son utilisation - Google Patents
Composition pharmaceutique de pembrolizumab et son utilisationInfo
- Publication number
- EP4329729A4 EP4329729A4 EP22796265.1A EP22796265A EP4329729A4 EP 4329729 A4 EP4329729 A4 EP 4329729A4 EP 22796265 A EP22796265 A EP 22796265A EP 4329729 A4 EP4329729 A4 EP 4329729A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- pembrolizumab
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2021112111A RU2791857C2 (ru) | 2021-04-27 | Фармацевтическая композиция пембролизумаба и ее применение | |
| PCT/RU2022/050140 WO2022231481A1 (fr) | 2021-04-27 | 2022-04-27 | Composition pharmaceutique de pembrolizumab et son utilisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4329729A1 EP4329729A1 (fr) | 2024-03-06 |
| EP4329729A4 true EP4329729A4 (fr) | 2025-04-02 |
Family
ID=83848424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP22796265.1A Pending EP4329729A4 (fr) | 2021-04-27 | 2022-04-27 | Composition pharmaceutique de pembrolizumab et son utilisation |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP4329729A4 (fr) |
| CN (1) | CN117835965A (fr) |
| AR (1) | AR125470A1 (fr) |
| CL (1) | CL2023003209A1 (fr) |
| CO (1) | CO2023014166A2 (fr) |
| CR (1) | CR20230527A (fr) |
| EC (1) | ECSP23081880A (fr) |
| JO (1) | JOP20230267A1 (fr) |
| MA (1) | MA62939A1 (fr) |
| MX (1) | MX2023012745A (fr) |
| PE (1) | PE20250072A1 (fr) |
| PY (1) | PY2231960A (fr) |
| TW (1) | TW202308692A (fr) |
| WO (1) | WO2022231481A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL322410A (en) * | 2023-02-16 | 2025-09-01 | Sun Pharmaceutical Ind Ltd | Stable protein complexes containing an antibody against PD1 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018204368A1 (fr) * | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations stables d'anticorps anti-récepteur de mort programmée 1 (pd-1) et leur utilisation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY188749A (en) * | 2015-04-17 | 2021-12-28 | Bristol Myers Squibb Co | Compositions comprising a combination of nivolumab and ipilimumab |
| US11608357B2 (en) * | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
| WO2018211517A1 (fr) * | 2017-05-16 | 2018-11-22 | Bhami's Research Laboratory, Pvt. Ltd. | Formulations de protéines à haute concentration ayant une viscosité réduite |
| WO2020097141A1 (fr) * | 2018-11-07 | 2020-05-14 | Merck Sharp & Dohme Corp. | Formulations stables d'anticorps du récepteur de mort programmé 1 (mp-1) et leurs méthodes d'utilisation |
-
2022
- 2022-04-26 TW TW111115864A patent/TW202308692A/zh unknown
- 2022-04-27 PE PE2023002957A patent/PE20250072A1/es unknown
- 2022-04-27 MX MX2023012745A patent/MX2023012745A/es unknown
- 2022-04-27 CN CN202280030892.2A patent/CN117835965A/zh active Pending
- 2022-04-27 WO PCT/RU2022/050140 patent/WO2022231481A1/fr not_active Ceased
- 2022-04-27 MA MA62939A patent/MA62939A1/fr unknown
- 2022-04-27 AR ARP220101106A patent/AR125470A1/es unknown
- 2022-04-27 CR CR20230527A patent/CR20230527A/es unknown
- 2022-04-27 PY PY202202231960A patent/PY2231960A/es unknown
- 2022-04-27 EP EP22796265.1A patent/EP4329729A4/fr active Pending
-
2023
- 2023-10-23 CO CONC2023/0014166A patent/CO2023014166A2/es unknown
- 2023-10-25 EC ECSENADI202381880A patent/ECSP23081880A/es unknown
- 2023-10-26 CL CL2023003209A patent/CL2023003209A1/es unknown
- 2023-10-26 JO JOJO/P/2023/0267A patent/JOP20230267A1/ar unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018204368A1 (fr) * | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations stables d'anticorps anti-récepteur de mort programmée 1 (pd-1) et leur utilisation |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023012745A (es) | 2023-11-09 |
| WO2022231481A1 (fr) | 2022-11-03 |
| CN117835965A (zh) | 2024-04-05 |
| MA62939A1 (fr) | 2024-02-29 |
| CR20230527A (es) | 2024-02-13 |
| JOP20230267A1 (ar) | 2023-10-26 |
| CO2023014166A2 (es) | 2024-02-05 |
| PY2231960A (es) | 2022-11-25 |
| TW202308692A (zh) | 2023-03-01 |
| PE20250072A1 (es) | 2025-01-13 |
| AR125470A1 (es) | 2023-07-19 |
| ECSP23081880A (es) | 2023-11-30 |
| EP4329729A1 (fr) | 2024-03-06 |
| CL2023003209A1 (es) | 2024-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4472967A4 (fr) | Agents de dégradation d'irak et leurs utilisations | |
| EP4074345A4 (fr) | Conjugué anticorps anti-claudine-médicament et son utilisation pharmaceutique | |
| EP4129283A4 (fr) | Association pharmaceutique et son utilisation | |
| EP3747022A4 (fr) | Imagerie et analyse de plaie | |
| EP3914252A4 (fr) | Composition pharmaceutique du nilotinib | |
| EP4023227A4 (fr) | Composition pharmaceutique et son application | |
| EP4499068A4 (fr) | Agents de dégradation d'irak et leurs utilisations | |
| EP4073071A4 (fr) | Utilisation et composition pharmaceutique de dérivés de phénylisoxazolyl méthylène-naphtalène-éther | |
| EP3981390A4 (fr) | Composition pharmaceutique de lacosamide et sa préparation pharmaceutique | |
| EP4293028A4 (fr) | Dérivé de smtp-7 et son utilisation | |
| EP4106870A4 (fr) | Compositions et utilisations thérapeutiques de cannabidiol | |
| EP4048298A4 (fr) | Préparation et utilisation d'hydrogels thérapeutiques | |
| EP3777866A4 (fr) | Composition pharmaceutique et application de cette dernière | |
| EP4071170A4 (fr) | Composition pharmaceutique, son procédé de préparation et son utilisation | |
| MA50368A (fr) | Nouveau dérivé de 1h-pyrazolopyridine et composition pharmaceutique le contenant | |
| EP4082614A4 (fr) | Composé acylsulfamide et son utilisation pharmaceutique | |
| EP3880183A4 (fr) | Préparation pharmaceutique de fruquintinib et son utilisation | |
| EP4365288A4 (fr) | Polynucléotide et composition médicinale | |
| EP4365183A4 (fr) | Composé stéroïde, composition pharmaceutique et utilisation associées | |
| EP4134068A4 (fr) | Composition de bendamustine et son utilisation | |
| EP4357367A4 (fr) | Composition pharmaceutique et son utilisation | |
| EP4456887A4 (fr) | Composition pharmaceutique | |
| EP3893843C0 (fr) | Compositions pharmaceutiques de furosémide et leurs utilisations | |
| EP4180040A4 (fr) | Composition pharmaceutique et son application | |
| EP4223313A4 (fr) | Composition pharmaceutique comprenant une combinaison de neutralisation acide-base et son application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20231116 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20250227 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/19 20060101ALI20250221BHEP Ipc: A61P 35/00 20060101ALI20250221BHEP Ipc: A61P 31/00 20060101ALI20250221BHEP Ipc: A61K 47/26 20060101ALI20250221BHEP Ipc: A61K 47/22 20060101ALI20250221BHEP Ipc: A61K 47/18 20170101ALI20250221BHEP Ipc: A61K 47/10 20170101ALI20250221BHEP Ipc: A61K 39/395 20060101ALI20250221BHEP Ipc: A61K 9/08 20060101AFI20250221BHEP |